

December 1, 2016



VolitionRx Limited to Attend Citi 2016 Global Healthcare Conference

Company to also participate in three additional Healthcare conferences in December

NAMUR, Belgium, Dec. 1, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced that it will attend the Citi 2016 Global Healthcare Conference being held on December 7-8, 2016 at The Lotte New York Palace in New York, NY.

At the Citi Conference, Jake Micallef, Chief Scientific Officer of Volition, and Scott Powell, Vice President of Investor Relations, will provide an update on Volition's business, clinical, regulatory and operational milestones, as well as the Company's recently announced product launch of its Nu.Q™ Colorectal Cancer Screening Triage Test.

Volition plans to also attend three more conferences this month in addition to Citi. The details of such conferences are as follows:

Event: The Benchmark Company, LLC Micro Cap Discovery Conference
Date: Thursday, December 1, 2016
Location: The Palmer House Hilton Hotel, Chicago, IL

Event: The Nordic-American Life Science Conference
Date: Thursday, December 1, 2016
Location: 10 on the Park, New York, NY

Event: LD Micro Main Event
Date: Tuesday – Thursday, December 6-8, 2016
Presentation Time: Tuesday, December 6th, 12:00 pm Pacific Time
Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA

Persons attending any of the above-referenced conferences who would like to schedule a 1-on-1 meeting with Volition management during such conference may do so by contacting Tirth Patel of Edison Advisors at tpatel@edisongroup.com or Scott Powell, Vice President of Investor Relations of Volition, at S.Powell@volitionrx.com.

About Volition

Volition is a life sciences company focused on developing diagnostic tests for cancer. The tests are based on the science of Nucleosomics[®], which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.

Volition's goal is to make the tests as easy and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. Volition's research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

For more information about Volition, visit Volition's website (<http://www.volitionrx.com>) or connect with us via:

Twitter: <https://twitter.com/volitionrx>

LinkedIn: <https://www.linkedin.com/company/volitionrx>

Facebook: <https://www.facebook.com/VolitionRx/>

YouTube: <https://www.youtube.com/user/VolitionRx>

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Louise Day, Volition

L.day@volitionrx.com

+44 (0)7557 774620

Tirth Patel, Edison Advisors

tpatel@edisongroup.com

+1 (646) 653 7035

Sarah Roberts, Vane Percy & Roberts

sarah@vanepercy.com

+44 (0)1737 821 890

Scott Powell, Volition

S.powell@volitionrx.com

+1 (646) 650 1351

Rachel Carroll, Edison Advisors

rcarroll@edisongroup.com

+44 (0)20 3077 5711

Nucleosomics®, NuQ®, Nu.Q™ and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/volitionrx-limited-to-attend-citi-2016-global-healthcare-conference-300371361.html>

SOURCE VolitionRx Ltd